Drug Profile
Topotecan/encequidar - Athenex
Alternative Names: Encequidar/topotecan - Athenex; Oral topotecan + oral encequidar - Athenex; Oral topotecan + oral HM30181A; Oral topotecan + oral HM30181A-US; Oratopo; Topotecan + HM30181ALatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Athenex
- Developer Athenex; Hong Kong Polytechnic University; McGill University
- Class Amides; Antineoplastics; Benzopyrans; Camptothecins; Isoquinolines; Small molecules; Tetrazoles
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 12 Sep 2023 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO)
- 12 Sep 2023 Discontinued - Preclinical for Cancer in Hong Kong (PO)
- 30 Mar 2022 Suspended - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO)